Xcell Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2,094	7,764	1,239	5,436	14,632
Short-Term Investments	300	35.67	120	120	-
Trading Asset Securities	4,512	1,002	-	-	-
Cash & Short-Term Investments	6,906	8,802	1,359	5,556	14,632
Cash Growth	-21.54%	547.78%	-75.55%	-62.03%	119.39%
Accounts Receivable	-114.09	54.71	282.87	264.4	159.42
Other Receivables	476.74	455.24	333.93	368.52	109.59
Receivables	362.65	509.96	616.8	632.92	269.01
Inventory	1,327	697.92	804.25	686.9	500.67
Prepaid Expenses	322.31	10.6	-	-	-
Other Current Assets	718.66	491.19	60.41	339.89	22.45
Total Current Assets	9,637	10,512	2,840	7,216	15,425
Property, Plant & Equipment	4,193	4,472	5,355	7,372	7,515
Long-Term Investments	879.6	1,099	34.78	31.69	19.81
Other Intangible Assets	694.06	537.35	125.05	307.51	238.75
Long-Term Accounts Receivable	-0	-0	-0	-0	-0
Other Long-Term Assets	317.7	269.81	2,113	582.39	503.45
Total Assets	15,721	16,890	10,468	15,509	23,702
Accounts Payable	217.14	125.57	133.66	90	227.29
Accrued Expenses	344.28	295.36	263.38	277.52	244.79
Short-Term Debt	3,500	3,500	4,000	4,000	4,000
Current Portion of Long-Term Debt	116.64	87.56	72.5	-	-
Current Portion of Leases	447.59	465.62	589.68	449.1	453.31
Other Current Liabilities	706.2	432.39	383.32	370.56	332.31
Total Current Liabilities	5,332	4,906	5,443	5,187	5,258
Long-Term Debt	1,016	1,132	1,148	870	870
Long-Term Leases	406.73	515.99	695.9	527.77	868.12
Pension & Post-Retirement Benefits	1,130	693.4	288.17	-	93.87
Other Long-Term Liabilities	699.43	520.26	510.64	440.67	387.31
Total Liabilities	8,583	7,769	8,085	7,026	7,477
Common Stock	8,647	5,459	4,582	4,380	4,376
Additional Paid-In Capital	64,140	57,993	42,711	39,913	39,860
Retained Earnings	-66,666	-55,717	-46,071	-36,835	-28,407
Comprehensive Income & Other	1,017	1,386	1,162	1,025	395.85
Total Common Equity	7,138	9,121	2,384	8,483	16,225
Shareholders' Equity	7,138	9,121	2,384	8,483	16,225
Total Liabilities & Equity	15,721	16,890	10,468	15,509	23,702
Total Debt	5,487	5,702	6,506	5,847	6,191
Net Cash (Debt)	1,419	3,100	-5,147	-290.75	8,441
Net Cash Growth	-54.22%	-	-	-	378.96%
Net Cash Per Share	121.84	309.93	-581.98	-33.21	1019.25
Filing Date Shares Outstanding	17.29	10.92	9.16	8.76	8.75
Total Common Shares Outstanding	17.29	10.92	9.16	8.76	8.75
Working Capital	4,305	5,605	-2,602	2,029	10,167
Book Value Per Share	412.74	835.38	260.10	968.50	1854.01
Tangible Book Value	6,444	8,584	2,258	8,176	15,986
Tangible Book Value Per Share	372.61	786.16	246.46	933.39	1826.73
Land	370.53	370.53	370.53	1,971	1,971
Buildings	1,624	1,624	1,624	1,624	1,624
Machinery	3,642	3,320	3,059	2,952	2,433
Construction In Progress	-	-	-	-	278.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.